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The history of inhaler technology goes back almost 250 years. The first time the word inhaler was used was related to the 'Mudge' Inhaler in 1778 \[[@CR1]\]. In modern inhalation therapy, there are four main device types. The first devices resembling nebulisers were introduced in the 1860s, metered dose inhalers (MDI) were developed in the 1950s, dry powder inhalers (DPI) in the 1980s and soft mist inhalers (SMI) after the year 2000.

In 2006, Chrystyn et al. \[[@CR2]\] proposed five qualities which are required for an 'ideal inhaler'. Firstly, the emitted dose must have appropriate aerodynamic characteristics to be as much as possible independent of a patient's characteristics and clinical condition. Secondly, delivery of the drug must be safe and effective, thus maximising the therapeutic effects locally, while minimising systemic effects. Thirdly, the inhaler must be easy and intuitive to use. Fourthly, the device must be appealing to the patient to promote adherence and proper use. And lastly, ideally, a single device type should include all of the patient's required inhalable treatments.

Since 2006, there has been an increased recognition of global environmental threats. There has therefore been increasing pressure to include environmental factors in the ideal features. To limit the depletion of the ozone layer, the permitted level of chlorofluorocarbons (CFC) produced was reduced from 150% of calculated levels of production and consumption to zero between 1986 and 2010 by the Montreal Protocol \[[@CR3]\]. In response to these changes, the pharmaceutical industry increased its focus on the development of dry powder inhalers \[[@CR4]\]. While pressurised MDIs (pMDIs) remain the most commonly prescribed type of inhaler \[[@CR5]\], even in the post-CFC era, they still pose an environmental hazard \[[@CR6]\], as the modern propellants (hydrofluorocarbons and hydrofluoroalkanes) are roughly 1300 times more potent than CO~2~ as greenhouse gases. In fact, the carbon footprint of pMDIs has been reported to be over 100-fold greater than that of DPIs \[[@CR7]\].

The properties of each device type, including pros and cons, are outlined in Table [1](#Tab1){ref-type="table"}: pMDIs facilitate patient-independent aerosolisation, but require sufficient coordination upon actuation; nebulisers allow delivery during normal breathing patterns, but are cumbersome to carry and need cleaning and servicing; SMIs are portable, but like pMDIs handling and co-ordination for dosing may be difficult for some subjects in comparison with DPIs; finally, DPIs are convenient and lightweight but rely upon patient inhalation technique to aerosolise the drug powder \[[@CR8]\]. Taking environmental considerations into account, DPIs, being portable and easy to use, offer an appealing option for pulmonary drug delivery. Choosing the right device for the right patient is not as straightforward as it might first appear. Myths and misconceptions persist---particularly with DPIs---and debunking these will help clinicians pick the best device for their patient. For these reasons, this opinion paper aims to discuss the benefits and drawbacks of DPIs, from both a device and a patient's perspective.Table 1Comparison of characteristics of different types of inhalersDPIpMDIBA-MDISMINebuliserNo spacerWith spacerMedicine stored inDry powderSuspension/solutionSuspension/solutionSuspension/solutionSolutionSolutionPropellant requiredNoYesYesYesNoNoBuilt in dose counter^a^YesNo/yesNo/yesNo/yesNo/yesNoHandheld/portableYesYesYes/noYesYesNoSingle handed use and manual dexterity in loading and using the deviceNo/YesYesNoYesYesNoBreath-actuatedYesNoNoYesNoNoCo-ordination between actuation and inhalation requiredNoYesNoNoYesNoInhalationFast and deep (forceful inhalation from the very beginning, 4--5 s)Slow and deep (4--5 s)Slow and deep (4--5 s)Slow and deep (4--5 s)Slow and deep (4--5 s)Normal breathingTime needed for one dose deliveryShortShortShortShortShortLong*DPI* dry powder inhaler, *BA-MDI* breath-actuated MDI, *pMDI* pressurised metered dose inhaler, *SMI* soft mist inhaler^a^Highly appreciated by the patients, hence increasingly incorporated and enhanced in devices

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

From Powder to Aerosol {#Sec2}
======================

Despite their apparent simplicity, dry powder inhalers are sophisticated devices. In order to deliver active drug to the respiratory tract, the user must inhale through the device. This inhalation provides energy which breaks up the compacted drug powder, a process called de-agglomeration, and transports this de-agglomerated drug into the lung \[[@CR9]\]. Most DPIs contain a micronised drug blended with carrier particles such as lactose that prevent aggregation and provide sufficient flowability. To enhance the aerosolisation of the drug particles, fine lactose particles are often added to the carrier lactose to saturate high-energy binding sites on the carrier lactose and form easily detachable aggregates with the drug particles. Both mechanisms contribute to higher fine particle dose, which is defined as the dose able to penetrate deep into the lungs \[[@CR10]--[@CR13]\].

When the patient activates the DPI and inhales, airflow through the device creates shear forces and airflow turbulence. As the powder is emitted from the inhaler, the drug particles separate from the carrier particles and are carried deep into the lungs, while the larger carrier particles end up in the oropharynx and are swallowed/cleared \[[@CR8]\]. Thus, the level of deposition into the lungs is determined by a combination of two factors: the patient's inspiratory effort and the device's properties (e.g. shape of the mouth piece, flow resistance and flow) \[[@CR14]\] \[[@CR15]\]. To achieve efficient aerosol dispersion, drug formulations have been developed in conjunction with varying DPI design elements, such as swirl chambers, grids and lacunas, to subsequently present varying degrees of airflow resistance. Hence, each DPI results in different pressure-drop and flow-rate characteristics. In general, the flow rate though a DPI is proportional to the square root of the pressure drop that the patient develops across it. The constant of proportionality is termed the device resistance \[[@CR16]\].

Counterintuitively, higher resistance is often an advantage with DPIs. With the exception of the Turbuhaler (AstraZeneca), medium-to-high-resistance inhalers require lower patient inspiratory flow rates for optimal performance (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR17]--[@CR22]\]. Generally, higher-resistance devices generate more turbulent flow, more effectively converting the work done by the patient to energy available for de-agglomeration of the drug particles \[[@CR23]--[@CR25]\]. In contrast, the Turbuhaler uses a built-in cyclone to de-agglomerate the formulation, and therefore has a minimum threshold for inspiratory flow rate to effectively aerosolise the drug particles \[[@CR26]\]. In breath-actuated DPI devices, a certain pre-determined threshold in inspiratory flow rate has to be achieved before the drug is released from the inhaler. This prevents drug release at low flow rates that would not be high enough to allow effective de-agglomeration and would therefore result in low pulmonary deposition. Devices at the lower end of the resistance spectrum use less manipulation of flow patterns through the inhaler, and therefore rely more on the patient generating a flow rate that achieves sufficient de-agglomeration. With these principles in mind, patients with impaired pulmonary function could benefit from devices with higher resistance \[[@CR21]\].Fig. 1Dry powder inhaler resistance and optimal peak inspiratory flow for adequate drug delivery

European and US pharmacopoeia recommend the use of a standardised pressure drop of 4 kPa for in vitro characterisation of DPI products. As this was originally intended as a method in quality control in the context of batch release, it is ill suited to produce data relevant to performance with patients. Recent publications are instead reporting the use of fixed ranges of inspiratory flow rates or patient population-specific percentiles when trying to simulate real-life conditions \[[@CR18], [@CR20], [@CR27]\]. Haidl et al. \[[@CR28]\] have suggested criteria for a successful inhalation manoeuvre, namely sufficient device-specific inhalation flow rate, flow acceleration, inhalation volume and inhaled volume after actuation. Based on this review, the peak inspiratory flow rate (PIF) of 30 L min^−1^ is sufficient for various DPIs of different operating principles, e.g. Easyhaler (reservoir; Orion), Handihaler (capsule; Boehringer--Ingelheim) and Ellipta (blister; GlaxoSmithKline). Patients' inspiratory efforts have been shown to vary between age ranges (from paediatric to geriatric) and indications (from asthma to COPD) \[[@CR22], [@CR29], [@CR30]\]. However, the expected PIF of 30 L min^−1^ seems to be well within reasonable limits. For example, when PIF was studied on the Easyhaler (a relatively high-resistance device compared with the Symbicort Turbuhaler) in adult and paediatric patients with asthma, as well as adults with COPD, the 10th, 50th and 90th percentiles for PIF were 44.7 L min^−1^, 61.1 L min^−1^ and 74.8 L min^−1^ \[[@CR18]\], respectively. Further, the dosing has been shown to be consistent for PIF values of 28.3--74.8 L min^−1^ \[[@CR31], [@CR32]\]. (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Comparison of two budesonide/formoterol DPIs 160/4.5 μg/dose, Easyhaler (**a**) and Turbuhaler (**b**) regarding the consistency of the delivered dose at different inhalation flow rates \[[@CR31]\]

Inhaler Use in Practice: Pitfalls and Successes {#Sec3}
===============================================

Drugs are only effective if they can reach their site of action. In pulmonary delivery, the inhaler adds an extra step and a further potential barrier. Clinicians working with patients will be only too aware that there are many possible ways to use an inhaler device incorrectly. Education is vital and continuous re-education is also required. Recently, this has been addressed by third parties (e.g. <https://www.rightbreathe.com>), who provide commercially independent training materials and educational videos on the use of inhalers, but more work is still needed. Melani et al. studied the user-associated mistakes made by 1664 adults with asthma and COPD who used MDIs and DPIs at home. The most common mistakes made with DPIs were exhaling into the inhaler before or after actuation and a lack of holding breath after the inhalation \[[@CR33]\]. Sandler et al. showed that relatively few inhaler-naïve adults were able to use an inhaler \[either the Spiromax (Teva), Easyhaler or Turbuhaler\] correctly without training (just over a third), but following careful guidance by a healthcare provider (HCP), \> 95% can master the technical aspects required for successful inhalation \[[@CR34]\]. Patient education is required at diagnosis, at regular intervals, and certainly if the inhaler device is changed. Continuous checking and coaching also promotes the HCP--patient partnership and the active involvement of the patient and reduces unscheduled health care utilisation in asthma and COPD \[[@CR35], [@CR36]\]. Mistakes in the use of the inhaler have been shown to affect outcomes, but no conclusive evidence has been demonstrated using direct comparisons between inhaler types or devices \[[@CR37]--[@CR40]\]. Taking into account that inhaler use has not improved during the last 40 years, substantial effort is needed from both HCPs and inhaler designers to rectify this issue \[[@CR41]\].

The range of different medications available for administration via inhalers is vast and may be a source of confusion, for HCPs and especially for lay people. Patients with asthma are often satisfied with their reliever, short-acting beta agonist (SABA)-only treatment, because of their quick onset of action and immediate relief of symptoms. This may lead patients to believe that their asthma is controlled by their reliever therapy; however regular SABA-use is associated with poor outcomes \[[@CR42], [@CR43]\]. Dispensing three or more canisters of SABA a year is associated with increased hospital attendance \[[@CR44]\], and more than 12 a year with risk of asthma deaths, \[[@CR45]\] even in patients with minimal symptoms \[[@CR46], [@CR47]\]. This highlights the need to educate patients regarding the functions of the different drugs that they are prescribed. In the most recent 2019 Global Initiative for Asthma (GINA) report, a trend to simplify the treatment regimen can be seen \[[@CR48]\]. The formerly used step 1 (SABA-only) treatment regimen was disregarded. Instead, with safety as the main priority, GINA now recommends that all patients with asthma should be prescribed inhaled steroids intermittently (in mild asthma) or continuously. GINA no longer recommends SABA as first-line treatment and recommends a combination of low-dose inhaled corticosteroids (ICS) and formoterol as needed in mild cases (less than 2 episodes of symptoms a month) and as an alternative to regular ICS in Step 2 of the GINA's stepwise asthma management approach. This treatment strategy has been shown to reduce serious exacerbations when compared with SABA-only and to be non-inferior when compared with daily ICS and SABA as needed \[[@CR49], [@CR50]\]. Furthermore, a real-world comparison of as-needed ICS-formoterol in GINA's stepwise asthma management approach, Step 1 and 2 patients with as-needed albuterol (salbutamol) demonstrated significantly lower asthma exacerbations in the as-needed ICS-formoterol group \[[@CR51]\]. As steps 1 and 2, according to the new GINA strategy, can now be managed with single combined treatment as needed it will simplify the treatment. It also makes use of the incorrect practices by patients with infrequent symptoms not using their regular medication \[[@CR52]\] and their urge for reliever therapy to control their disease. Therefore, the new GINA report takes a step towards a Maintenance and Reliever Therapy (MART) regimen, in which control and reliever therapy is combined in a single product. The concept of simplifying the treatment regimen has previously been employed in other fields of medicine. For example, when treating hypertension and dyslipidemia, medication may be combined to a single tablet to increase patient adherence \[[@CR53]\]. It is worth mentioning that the studies cited in the new GINA report were conducted only with budesonide-formoterol combination therapy, and the clinical data have been extrapolated to also include other ICS. The recommendations are currently off-label and specifically include low-dose ICS-formoterol preparations to take advantage of the rapid action of formoterol.

In a cost--benefit analysis by Haahtela et al., Finnish asthma-related healthcare costs decreased by 14% between 1987 and 2013 despite a 3-fold increase in the number of diagnoses and an increase in medication costs \[[@CR54]\]. As with the latest GINA guidelines, one of the cornerstones of the Finnish asthma program was to start inhaled corticosteroids as first-line treatment for all patients. The results from the program suggest that increased disease control not only improves patients' quality of life but also provides wider societal benefits (e.g. economic benefits and improvements in integrated care) \[[@CR55]\].

When compared with other types of inhalers, DPIs have a markedly different risk profile concerning the ambient environment. While they resist microbiological contamination extremely well, they are often susceptible to changes in their physical composition. For example, changes in crystallinity or agglomeration due to moisture may result in decreased performance of the product \[[@CR56]\]. When applying for marketing approval, all inhalers must have evidence that they work well if stored according to their summary of product characteristics. Therefore, patient training should not be constrained to the use of an inhaler, but should also include handling and storing of the device.

Inhalers are for Patients {#Sec4}
=========================

From the patient's perspective, the requirements for an ideal inhaler can be summarised with six E's (Fig. [3](#Fig3){ref-type="fig"}). An inhaler must be *Effective*; i.e. able to deliver the aerosols with particle sizes of respirable range and independent, as much as possible, of the inhalation volume and flow rate. This minimises the variation between patients, but also guarantees effective treatment when a single patient's clinical parameters vary during treatment. Successful delivery straight to the site of action also allows the drug to act with minimal adverse effects. An inhaler must also be *Efficient*, i.e. easy to handle and able to be used with relatively few handling steps; these properties contribute to compliance and error-free handling. An *Engaging* design promotes patient satisfaction and adherence, leading to better treatment outcomes. Despite all the training and efforts of the HCPs, patients will continue to make errors with their inhalers; therefore, a well-designed inhaler is *Error-tolerant* and will minimise the effects of at least the most common user errors. An inhaler should also be *Easy-to-teach*; when teaching the use of an inhaler is easy and fast, the HCP can check the patient's inhaler technique more easily and retrain the patient in using their device. Improvements in patients' technical proficiency are likely to result in better treatment outcomes as the doses are more consistently delivered to the site of action. Chronic diseases as asthma and COPD are not only problematic for patients themselves, but provide a considerable societal burden; therefore, an ideal inhaler is also *Easy-to-switch to* when needed (e.g. at the population level, for cost-effectiveness reasons).Fig. 3Six E's

Patients of all ages have been reported to be particularly poorly adherent to inhaled medication \[[@CR57], [@CR58]\]. To address this problem, many companies have developed web-based information platforms (e.g. <https://www.wehale.life/> \[Orion pharma\] and <https://www.asthma.com/>;Glaxo-Smith Kline) and inhaler-mounted smart devices, to give advice and feedback to the patient. Current guidelines on asthma and COPD promote the active involvement of the patient when choosing the inhaler. Satisfaction with an inhaler has been shown to relate to adherence and asthma control \[[@CR59]\]. Differences in satisfaction between inhalers have been reported to arise from convenience-related factors such as portability, weight and size, and from usability factors such as preparation and use \[[@CR60]\]. Several studies have reported therapeutic equivalence and successful switches between the inhalers (e.g. from Turbuhaler to Aerolizer, Spiromax, Easyhaler and Novolizer) \[[@CR61]--[@CR64]\]. An example of a large scale switch in real-life practice comes from Norway, where the health authority (Statens legemiddelverk) included the Bufomix Easyhaler and Duoresp Spiromax in its switch regimen of DPIs containing budesonide/formoterol in Norwegian pharmacies, starting on July 1, 2018 \[[@CR65]\].

Conclusions {#Sec5}
===========

In the market, there are many devices which are capable of delivering the drugs to the lungs of the patient. The myriad of devices and complex physics involved in the delivery makes it difficult for clinicians to choose the right device for their patients. For the majority of patients, there is a sufficiently effective combination of drug molecules available for use. However, poor adherence and incompetence with the device remain as frequent problems in inhalation therapy. Most patients are able to use nebulisers and pMDIs as well as high- and low-resistance DPIs. There is rarely a single best device for any given patient, and the choice should be made with the patient to take into account the parameters which are important to the actual user, such as size, portability or environmental factors. These properties valued by the patients may be medically irrelevant but through adherence could be the defining factor in the success of the treatment.
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